Development of a functional assay to test for homologous recombination in ovarian cancer
Background: PARP inhibitors selectively target homologous recombination (HR) defective cells and show good clinical activity in hereditary breast and ovarian cancer associated with BRCAl12 mutations. A high proportion (up to 50%) of sporadic epithelial ovarian cancers (EOC) could be deficient in HR...
Main Author: | Mukhopadhyay, Asima |
---|---|
Published: |
University of Newcastle Upon Tyne
2011
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577481 |
Similar Items
-
Chemokines, leukocytes and human ovarian cancer
by: Negus, R. P. M.
Published: (1998) -
Molecular determinants of the response to therapy in ovarian cancer
by: Ricci, Francesca
Published: (2013) -
The role of Rab35 in androgen sensitive ovarian cancer
by: Hoo, San Soo
Published: (2013) -
The p53 family, septin scaffolds and epithelial ovarian cancer
by: Hinds, Lynsey
Published: (2013) -
The proliferative activity of interferon on ovarian cancer : in vitro and vivo models
by: Wall, Lucy Rosalind
Published: (2002)